文献速递肝病

恩替卡韦与替诺福韦对韩国初治慢性乙型肝炎预后影响的多中心研究

A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
PubMed 文献 · J Hepatol · 2019-04-06

该多中心研究纳入2012至2014年4家教学医院初治慢性乙型肝炎患者2897例,比较恩替卡韦(ETV)与富马酸替诺福韦二吡呋酯(TDF)对肝细胞癌(HCC)及死亡或原位肝移植(OLT)累积概率的影响。结果显示两组年度HCC发病率及死亡或OLT发病率均无统计学差异,结论需进一步研究验证。

要点

  • ETV组与TDF组年度HCC发病率分别为1.92与1.69/100人年,调整HR 0.975(p=0.852),无统计学差异。
  • 两组年度死亡或OLT发病率分别为0.52与0.53/100人年,调整HR 1.202(p=0.451),无统计学差异。
  • 倾向性评分匹配及IPTW分析结果一致,代偿性肝硬化患者中亦无统计学差异(所有p>0.05)。

核心结论

  • ETV组与TDF组在HCC及死亡或OLT方面的总体预后无统计学差异。
  • 原文结论指出需进一步研究以验证本研究结果。

研究设计与样本

  • 多中心研究,自2012至2014年从4家学术教学医院招募初治慢性乙型肝炎患者。
  • 患者以ETV或TDF作为一线抗病毒药物,排除入组时存在失代偿性肝硬化或HCC者。
  • 共纳入2897例患者,ETV组1484例,TDF组1413例。
  • 评估HCC及死亡或OLT的累积概率,并采用倾向性评分匹配和逆概率治疗加权(IPTW)分析。

主要发现

  • ETV组与TDF组年度HCC发病率分别为1.92与1.69/100人年,调整HR 0.975(p=0.852),无统计学差异。
  • 倾向性评分匹配分析HR 1.021(p=0.884),IPTW分析HR 0.998(p=0.988)。
  • ETV组与TDF组年度死亡或OLT发病率分别为0.52与0.53/100人年,调整HR 1.202(p=0.451),无统计学差异。
  • 倾向性评分匹配分析HR 1.248(p=0.385),IPTW分析HR 1.239(p=0.360)。
  • 代偿性肝硬化患者中上述结果一致(所有p>0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步研究以验证本研究结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: It is currently unclear which antiviral agent, entecavir (ETV) or tenofovir disoproxil fumarate (TDF), is superior for improving prognosis in patients with chronic hepatitis B (CHB). Here, we assessed the ability of these 2 antivirals to prevent liver-disease progression in treatment-naïve patients with CHB. METHODS: From 2012 to 2014, treatment-naïve patients with CHB who received ETV or TDF as a first-line antiviral agent were recruited from 4 academic teaching hospitals. Patients with decompensated cirrhosis or hepatocellular carcinoma (HCC) at enrollment were excluded. Cumulative probabilities of HCC and death or orthotopic liver transplant (OLT) were assessed. RESULTS: In total, 2,897 patients (1,484 and 1,413 in the ETV and TDF groups, respectively) were recruited. The annual HCC incidence was not statistically different between the ETV and TDF groups (1.92 vs. 1.69 per 100 person-years [PY], respectively; adjusted hazard ratio [HR] 0.975 [p = 0.852] by multivariate analysis). Propensity score (PS)-matched and inverse probability of treatment weighting (ITPW) analyses yielded similar patterns of results (HR 1.021 [p = 0.884] and 0.998 [p = 0.988], respectively). The annual incidence of death or OLT was not statistically different between the ETV and TDF groups (0.52 vs. 0.53 per 100 PY, respectively; adjusted HR 1.202 [p = 0.451]). PS-matched and ITPW analyses yielded similar patterns of results (HR 1.248 [p = 0.385] and 1.239 [p = 0.360], respectively). These findings were consistently reproduced in patients with compensated cirrhosis (all p >0.05). CONCLUSIONS: The overall prognosis in terms of HCC and death or OLT was not statistically different between the ETV and TDF groups. Further studies are needed to validate our results. LAY SUMMARY: It is currently unclear which antiviral agent, entecavir or tenofovir disoproxil fumarate, is superior for improving prognosis in patients with chronic hepatitis B virus infection. In this analysis we found that there was no difference in terms of overall prognosis, including risk of hepatocellular carcinoma, death, or the need for a liver transplant, in patients receiving either antiviral.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kim SU, Seo YS, Lee HA, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. J Hepatol. 2019. PMID: 30959156. doi:10.1016/j.jhep.2019.03.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。